RedHill Biopharma (RDHL) Cash from Financing Activities (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Cash from Financing Activities data on file, last reported at $14.9 million in Q2 2022.

• Cash from Financing Activities for Q2 2022 came in at $14.9 million, up 943.24% year-over-year; the trailing twelve-month figure through Jun 2022 was $26.5 million (down 65.43% YoY), and the FY2025 annual result was $7.3 million, down 7.88% from the prior year.
• Cash from Financing Activities advanced to $14.9 million in Q2 2022 per RDHL's latest filing, from -$4.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $59.1 million in Q1 2020 and troughed at -$4.9 million in Q1 2022.
• A 5-year average of $14.4 million and a median of $7.9 million in 2020 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2018 and 2021: Cash from Financing Activities surged 78406.67% in 2018, then tumbled 132.41% in 2021.
• A 5-year view of Cash from Financing Activities shows it stood at $18.4 million in 2018, then jumped by 96.67% to $36.1 million in 2019, then slumped by 78.0% to $7.9 million in 2020, then jumped by 121.25% to $17.6 million in 2021, then dropped by 15.11% to $14.9 million in 2022.
• Business Quant data shows RDHL's Cash from Financing Activities at $14.9 million in Q2 2022, -$4.9 million in Q1 2022, and $17.6 million in Q4 2021.